Person: TİGEN, ELİF
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
TİGEN
First Name
ELİF
Name
9 results
Search Results
Now showing 1 - 9 of 9
Publication Open Access Drug eruption: A mimicker of Coronavirus disease-2019 rash(2022-01-01) ERGUN, SAFİYE ATLAS TÜLİN; SEVEN, SEDA; SEÇKİN GENÇOSMANOĞLU, DİLEK; TİGEN, ELİF; AKTAŞ, MERYEM; ERGUN S. A. T., Ergenc I., SEVEN S., SEÇKİN GENÇOSMANOĞLU D., CÖMERT ÖZER E., AKTAŞ M., TİGEN E.Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections can be associated with several cutaneous lesions, among which maculopapular rash is the most common. A maculopapular rash can also be induced by medications used for Coronavirus disease-2019 (COVID-19) treatment. The distinction between viral rash and drug eruption may be difficult especially in case of several medication use for COVID-19. Thus, this study aimed to describe cutaneous manifestations in six patients with COVID-19 and highlight dues for distinguishing SARS-CoV-2-related rash and drug eruption. Between March and June 2020, 1,492 patients were hospitalized for COVID-19 and treated with hydroxychloroquine in Marmara University Hospital. Among them, six cases were consulted for possible COVID-19-related rash or drug reaction. Hydroxychloroquine was given as monotherapy in one patient. All six patients developed an erythematous, symmetrical, and maculopapular eruption that mainly affected the trunk, axilla, and genitocrural region, 5-21 days after the onset of COVID-19 symptoms. Five patients developed rash in 4-11 days after treatment completion. Pruritus was severe. All were treated with topical corticosteroids and oral antihistamines, which provided partial relief. The resolution of the eruption was typically slow, which took a few weeks. A long period between the COVID-19 symptoms and the eruption, as well as slow recovery, is in favor of drug eruption. The effects of co-existent viral infection, a well-known promoting drug eruption factor, in facilitating adverse drug reaction in patients with COVID-19 needs further observations and research.Publication Metadata only Prevalence of cardiovascular disease (cvd) and comparison of risk category predictions of systemic coronary risk evaluation 2 (score2) and four other cvd risk calculators among plwhiv in Turkey(2022-10-01) TİGEN, ELİF; KORTEN, VOLKAN; TİGEN E., Gokengin D., Ozdemir H. O. , Akalin H., Kaya B., Deveci A., Inan A., Inan D., Altunsoy A., Ozel A., et al.Publication Open Access Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter ephesus study(2023-09-28) TİGEN, ELİF; Sipahi O. R., Akyol D., Ormen B., Cicek-Senturk G., Mermer S., ÖNAL U., Amer F., Saed M. A., Ozdemir K., Tukenmez-Tigen E., et al.BACKGROUND: Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM). MATERIALS/METHODS: This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018. RESULTS: Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34). CONCLUSIONS: Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci.Publication Metadata only Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic(2024-01-01) ÜNDER, DUYGU; ENVER, CÜNEYD; DEMİRCİ, MUHAMMED YASİR; AYHAN, YUNUS EMRE; ÖZGAN, BETÜL; İLERLER, ENES EMİR; OKUYAN, BETÜL; ERTÜRK ŞENGEL, BUKET; KOCAKAYA, DERYA; SİLİ, ULUHAN; TİGEN, ELİF; KARAKURT, SAİT; KORTEN, VOLKAN; SANCAR, MESUT; ÜNDER D., ENVER C., DEMİRCİ M. Y., AYHAN Y. E., ÖZGAN B., İLERLER E. E., OKUYAN B., ERTÜRK ŞENGEL B., KOCAKAYA D., SİLİ U., et al.Objectives: Drug-related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist-led medication review in hospitalized probable patients with coronavirus disease-2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in Türkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician’s acceptance rate of clinical pharmacists’ recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug-related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.Publication Open Access Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting(2022-05-01) TİGEN, ELİF; Isler B., Ozer B., ÇINAR G., ASLAN A. T., Vatansever C., Falconer C., Dolapci I., Simsek F., TÜLEK N., Demirkaya H., et al.A prospective, multicentre observational cohort study of carbapenem-resistant Klebsiella spp. (CRK) bloodstream infections was conducted in Turkey from June 2018 to June 2019. One hundred eighty-seven patients were recruited. Single OXA-48-like carbapenemases predominated (75%), followed by OXA-48-like/NDM coproducers (16%). OXA-232 constituted 31% of all OXA-48-like carbapenemases and was mainly carried on ST2096. Thirty-day mortality was 44% overall and 51% for ST2096. In the multivariate cox regression analysis, SOFA score and immunosuppression were significant predictors of 30-day mortality and ST2096 had a non-significant effect. All OXA-48-like producers remained susceptible to ceftazidime-avibactam.Publication Open Access Topical cidofovir-related acute kidney injury in a kidney transplant recipient(2022-10-01) VELİOĞLU, ARZU; TİGEN, ELİF; ÖZGEN, ZÜLEYHA; TUĞLULAR, ZÜBEYDE SERHAN; VELİOĞLU A., Erdogan E., TİGEN E., ÖZGEN Z., TUĞLULAR Z. S.Publication Metadata only Prevalence of polypharmacy and potential drug-drug interactions associated with risk factors in the era of hiv integrase inhibitors: A prospective clinical study(2023-02-01) YAĞÇI ÇAĞLAYIK, DİLEK; TİGEN, ELİF; SİLİ, ULUHAN; ERTÜRK ŞENGEL, BUKET; KORTEN, VOLKAN; Altunal L. N., YAĞÇI ÇAĞLAYIK D., Ozel A. S., TİGEN E., SİLİ U., ERTÜRK ŞENGEL B., Aydin M., KORTEN V.People living with human immunodeficiency virus (PLWH), with the availability of modern antiretroviral drugs, have multiple comorbidities, which increase the risk of polypharmacy and potential drug-drug interactions (PDDIs). This is a particularly important issue for the aging population of PLWH. This study aims to review the prevalence and risk factors for PDDIs and polypharmacy in the era of HIV integrase inhibitors. A cross-sectional, two-center, prospective observational study was conducted on Turkish outpatients between October 2021 and April 2022. Polypharmacy was defined as the use of >= 5 non-HIV medications, excluding over-the-counter (OTC) drugs, and PDDIs were classified using the University of Liverpool HIV Drug Interaction Database (harmful/red flagged and potentially clinically relevant/amber flagged). The median age of the 502 PLWH included in the study was 42 +/- 12.4 years and 86.1% were males. Most individuals (96.4%) were given integrase-based regimens (unboosted 68.7% and boosted 27.7%). In total, 30.7% of individuals were taking at least one OTC drug. The prevalence of polypharmacy was 6.8% (9.2% when OTC drugs were included). During the study period, the prevalence of PDDIs was 1.2% for red flag PDDIs and 16% for amber flag PDDIs. CD4(+) T cell count >500 cells/mm(3), number of comorbidities >= 3, comedication with drugs affecting blood and blood-forming organs, cardiovascular drugs, and vitamin/mineral supplements were associated with red flag or amber flag PDDIs. Drug interaction prevention is still important in HIV care. Individuals with multiple comorbidities should be closely monitored for non-HIV medications to prevent PDDIs.Publication Open Access Comparison of Turkish version of the medical outcomes study-HIV health survey with short form health survey-36 in people living with human immunodeficiency virus(2022-07-01) TİGEN, ELİF; ÖZBEN SADIÇ, BESTE; KORTEN, VOLKAN; ERTÜRK ŞENGEL, BUKET; TİGEN E., ERTÜRK ŞENGEL B., ÖZBEN SADIÇ B., KORTEN V.Background/aim Several questionnaires have been developed to evaluate the quality of life (QoL) for people living with human immunodeficiency virus (HIV). The aim of this study was to compare Turkish version of the Medical Outcomes Study-HIV Health Survey (MOS-HIV) with Short Form Health Survey (SF-36) in people with HIV. Patients and methods A hundred and 14 patients with HIV were consecutively included. The MOS-HIV and SF-36 questionnaires were applied to all patients at the same day. MOS HIV included 35 items and assessed general health perceptions (GH), physical functioning (PF), social functioning (SF), mental health (MH), bodily pain (P), cognitive functioning, health distress, overall QoL, health transition, role functioning (RF), energy/vitality (EV), physical (Physical health summary score) and mental (MHSS) health summary scores. SF-36 included 36 items and measured eight domains of health concepts including SF, PF, P, RF, GH, role emotional, vitality (V) and MH. Correlation analysis and Bland- Altman plots were used to compare the MOS-HIV and SF-36 questionnaires. Results GH, PF, P, RF, EV, SF, and MH domains of the MOS-HIV were significantly correlated with those of SF 36. The agreement between the tests were 91.2% for PF, 92.1% for RF and pain, 94.7% for GH, 95.6% for EV, 92.1% for SF and 93.9% for MH. Conclusion Turkish version of the MOS HIV showed moderate correlations and agreement with SF 36 suggesting its use as an alternative to SF 36 in assessing QoL in these patients.Publication Open Access Belirgin kardiyovasküler hastalığı olmayan hastalarda COVID-19 mRNA aşısının elektrokar-diyografik parametreler üzerinde herhangi bir etkisi var mı?(2022-09-01) KEPEZ, ALPER; TİGEN, ELİF; Küp A., Çelik M., Uslu A., Külahçıoğlu Ş., Tükenmez Tigen E., Demir S., Gülşen K., İzci S., Uygun Kızmaz Y., Kepez A.Objective: Electrocardiographic alterations were investigated following the second dosage of COVID-19 mRNA vaccination. Methods: A total of 260 individuals after two doses of COVID-19 vaccine with Pfizer-BioNTech were included in the study. The electrocardiographic parameters recorded at baseline and approximately one week later after two doses of Pfizer-BioNTech vaccine were compared for all patients. Results: PR interval was increased and QTc maximum interval was decreased significantly after second dose COVID-19 mRNA vaccination. Baseline and post-second dose vaccination states regarding P wave dispersion and QT dispersion/Tp-e interval which have been recognized to imply inhomogeneous atrial conduction and heterogeneity in ventricular repolarization were similar between groups. Conclusion: Our findings suggest that there should be no concern related to asymptomatic involvement of the myocardium subsequent the second dose of COVID-19 mRNA vaccination.